FR2449084B1 - - Google Patents

Info

Publication number
FR2449084B1
FR2449084B1 FR8002589A FR8002589A FR2449084B1 FR 2449084 B1 FR2449084 B1 FR 2449084B1 FR 8002589 A FR8002589 A FR 8002589A FR 8002589 A FR8002589 A FR 8002589A FR 2449084 B1 FR2449084 B1 FR 2449084B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR8002589A
Other languages
French (fr)
Other versions
FR2449084A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaken Pharmaceutical Co Ltd
Original Assignee
Kaken Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP1721979A external-priority patent/JPS55111470A/ja
Priority claimed from JP1721879A external-priority patent/JPS55111469A/ja
Priority claimed from JP1786879A external-priority patent/JPS55111485A/ja
Priority claimed from JP2138079A external-priority patent/JPS55113767A/ja
Application filed by Kaken Chemical Co Ltd filed Critical Kaken Chemical Co Ltd
Publication of FR2449084A1 publication Critical patent/FR2449084A1/fr
Application granted granted Critical
Publication of FR2449084B1 publication Critical patent/FR2449084B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR8002589A 1979-02-19 1980-02-06 Nouveaux derives de geldanamycine, leur procede de preparation et leur application en therapeutique Granted FR2449084A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP1721979A JPS55111470A (en) 1979-02-19 1979-02-19 Geldanamycin derivative, its preparation, antitumor drug comprising it as active ingredient
JP1721879A JPS55111469A (en) 1979-02-19 1979-02-19 Novel geldanamycin derivative, its preparation, and antitumor drug comprising it as active ingredient
JP1786879A JPS55111485A (en) 1979-02-20 1979-02-20 Novel geldanamycin derivative, its preparation, and antitumor drug comprising it as active ingredient
JP2138079A JPS55113767A (en) 1979-02-27 1979-02-27 Novel geldanamycin derivative, its preparation and antitumorigenic agent containing the same as effective component

Publications (2)

Publication Number Publication Date
FR2449084A1 FR2449084A1 (fr) 1980-09-12
FR2449084B1 true FR2449084B1 (en:Method) 1983-12-23

Family

ID=27456741

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8002589A Granted FR2449084A1 (fr) 1979-02-19 1980-02-06 Nouveaux derives de geldanamycine, leur procede de preparation et leur application en therapeutique

Country Status (8)

Country Link
US (1) US4261989A (en:Method)
AU (1) AU532333B2 (en:Method)
CA (1) CA1113935A (en:Method)
DE (1) DE3006097A1 (en:Method)
FR (1) FR2449084A1 (en:Method)
GB (1) GB2042523B (en:Method)
IT (1) IT1147315B (en:Method)
NL (1) NL8000857A (en:Method)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3234203A1 (de) * 1981-09-17 1983-07-07 Takeda Chemical Industries, Ltd., Osaka Macbecin-derivate und deren herstellung
US4578391A (en) * 1982-01-20 1986-03-25 Yamanouchi Pharmaceutical Co., Ltd. Oily compositions of antitumor drugs
JPS59102398A (ja) * 1982-12-03 1984-06-13 Takeda Chem Ind Ltd 新規抗生物質およびその製造法
EP0664702A1 (en) * 1992-10-14 1995-08-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Tumoricidal activity of benzoquinonoid ansamycins against prostate cancer and primitive neural malignancies
US5387584A (en) * 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
CA2166320A1 (en) * 1993-06-29 1995-01-12 Randall James Gallaschun Ansamycin derivatives as antioncogene and anticancer agents
US5932566A (en) * 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
EP0828418A4 (en) * 1995-05-02 2000-03-29 Univ California INDUCTION OF THERMOTOLERANCE WITH BENZOCHINOIDS ANSAMYCINES
EP1023315B1 (en) 1997-05-14 2010-03-10 Sloan-Kettering Institute For Cancer Research Methods and compositions for destruction of selected proteins
US6852496B1 (en) 1997-08-12 2005-02-08 Oregon Health And Science University Methods of screening for agents that promote nerve cell growth
US6747055B1 (en) 1998-07-17 2004-06-08 The United States Of America As Represented By The Department Of Health And Human Services Water-soluble drugs and methods for their production
EP1098666B1 (en) 1998-07-17 2013-01-16 The United States of America, represented by the Secretary, Department of Health and Human Services Water-soluble drugs and methods for their production
EP1137427A1 (en) * 1998-12-07 2001-10-04 Ecosmart Technologies Inc. Cancer treatment composition and method using natural plant essential oils with signal transduction modulators
US6174875B1 (en) * 1999-04-01 2001-01-16 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
EP1169319A4 (en) * 1999-04-09 2005-02-09 Sloan Kettering Institutefor C METHODS AND COMPOSITIONS FOR DEGRADING AND / OR INHIBITING TYROSINE KINASES BELONGING TO THE HER FAMILY
US7238682B1 (en) 1999-04-09 2007-07-03 Sloan-Kettering Institute For Cancer Research Methods and compositions for degradation and/or inhibition of HER-family tyrosine kinases
US6979574B1 (en) * 1999-08-06 2005-12-27 Institut Fuer Diagnostik Forshung Gmbh Process for detecting binding reactions with use of the measurement of the relaxation of the double refraction of magnetic particles
WO2002002123A1 (en) * 2000-06-29 2002-01-10 Trustees Of Boston University Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders
JP2004505044A (ja) 2000-07-28 2004-02-19 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ 細胞増殖性障害およびウイルス感染の治療方法
KR20030065502A (ko) 2000-11-02 2003-08-06 슬로안-케테링인스티튜트퍼캔서리서치 에이치에스피90 저해제를 이용한 세포독성 제제의 효능을향상시키는 방법
EP1423080A4 (en) * 2001-03-01 2009-06-03 Conforma Therapeutics Corp PROCESS FOR TREATING PROLIFERATIVE GENETIC DISORDERS WITH HSP90 INHIBITORS
SI21369A (sl) * 2001-03-30 2004-06-30 The United States Of America, Represented By The Secretary, Geldanamicinski derivat in postopek zdravljenja raka z uporabo le-tega
CA2447066A1 (en) * 2001-05-23 2002-11-28 Sloan Kettering Institute For Cancer Research Method of treatment for cancers associated with elevated
EP1420747A4 (en) * 2001-08-06 2010-06-02 Kosan Biosciences Inc ANSAMYCIN BENZOQUINONE
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
EP1435939B1 (en) * 2001-09-24 2008-02-27 Conforma Therapeutic Corporation Process for preparing 17-allyl amino geldanamycin (17-aag) and other ansamycins
EP1923061A1 (en) 2001-09-24 2008-05-21 Conforma Therapeutic Corporation Process for preparing 17-Allyl amino geldanamycin (17-AAG) and other ansamycins
US7465718B2 (en) * 2002-02-08 2008-12-16 Conforma Therapeutics Corporation Ansamycins having improved pharmacological and biological properties
AU2003226285B2 (en) * 2002-04-10 2008-01-03 Conforma Therapeutics Corporation Ansamycin formulations and methods for producing and using same
US20060148776A1 (en) * 2003-03-13 2006-07-06 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
US7691838B2 (en) * 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
US20050020557A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
US20050054625A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
US20050026893A1 (en) * 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
US20050054589A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
US20050020534A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
WO2005009345A2 (en) * 2003-06-13 2005-02-03 Kosan Biosciences, Inc. 2-desmethyl ansamycin compounds
US6875863B1 (en) 2003-11-12 2005-04-05 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
CA2545457A1 (en) 2003-11-12 2005-06-23 Kosan Biosciences, Inc. 11-o-methylgeldanamycin compounds
US6887993B1 (en) 2003-11-12 2005-05-03 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6855705B1 (en) 2003-11-12 2005-02-15 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US20060019941A1 (en) * 2003-12-23 2006-01-26 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
KR101154351B1 (ko) * 2003-12-23 2012-06-15 인피니티 디스커버리, 인코포레이티드 암 치료를 위한 벤조퀴논-함유 안사마이신의 유사체
WO2005072766A2 (en) * 2004-01-27 2005-08-11 Boys Town National Research Hospital Peptides that bind to hsp90 proteins
ZA200607248B (en) 2004-03-15 2009-02-25 Sunesis Pharmaceutical Inc SNS-595 and methods of using the same
US20050267087A1 (en) * 2004-04-28 2005-12-01 Vassiliki Poulaki Inflammatory eye disease
US20050256097A1 (en) * 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
US7259156B2 (en) * 2004-05-20 2007-08-21 Kosan Biosciences Incorporated Geldanamycin compounds and method of use
WO2006034147A2 (en) * 2004-09-16 2006-03-30 Abraxis Bioscience, Inc. Compositions and methods for the preparation and administration of poorly water soluble drugs
US20060067953A1 (en) * 2004-09-29 2006-03-30 Conforma Therapeutics Corporation Oral pharmaceutical formulations and methods for producing and using same
CN105688289A (zh) * 2005-02-18 2016-06-22 阿布拉西斯生物科学公司 用于整合入医疗装置的疏水性改善的药物
CA2602257A1 (en) * 2005-03-30 2006-10-05 Conforma Therapeutics Corporation Alkynyl pyrrolopyrimidines and related analogs as hsp90-inhibitors
EP1871361A2 (en) * 2005-04-07 2008-01-02 Conforma Therapeutics Corporation Phospholipid-based pharmaceutical formulations and methods for producing and using same
EP1871343A2 (en) 2005-04-12 2008-01-02 Wisconsin Alumni Research Foundation Micelle composition of polymer and passenger drug
CA2604424A1 (en) * 2005-04-29 2006-11-09 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-aag or 17-ag or a prodrug of either in combination with a proteasome inhibitor
MX2007013494A (es) * 2005-04-29 2008-01-24 Kosan Biosciences Inc Metodo para tratar mieloma multiple utilizando 17-aag o 17-ag o un profarmaco de ya sea 17-aag o 17-ag.
US20080032719A1 (en) * 2005-10-01 2008-02-07 Outland Research, Llc Centralized establishment-based tracking and messaging service
WO2007002093A2 (en) * 2005-06-21 2007-01-04 Infinity Discovery, Inc. Ansamycin formulations and methods of use thereof
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
US20070105874A1 (en) * 2005-09-23 2007-05-10 Conforma Therapeutics Corporation Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors
US20090042847A1 (en) * 2005-11-23 2009-02-12 Kosan Biosciences Incorporated 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
US7648976B2 (en) * 2005-11-23 2010-01-19 Bristol-Myers Squibb Company 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
CA2631680A1 (en) * 2005-12-01 2007-06-07 Conforma Therapeutics Corporation Compositions containing ansamycin
US20070167422A1 (en) * 2006-01-18 2007-07-19 Yu Kwok S Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
US8658633B2 (en) * 2006-02-16 2014-02-25 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
EP2354138A1 (en) 2006-06-12 2011-08-10 Sunesis Pharmaceuticals, Inc. Compounds and compositions for treatment of cancer
EP3025712A1 (en) * 2006-08-02 2016-06-01 Sunesis Pharmaceuticals, Inc. Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid and cytarabine (ara-c) for the treatment of leukemia
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
US7855192B2 (en) * 2007-01-26 2010-12-21 Kosan Biosciences, Inc. Macrolactams by engineered biosynthesis
WO2008118601A2 (en) * 2007-02-27 2008-10-02 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Radiolabeled affibody molecules
BRPI0810178A2 (pt) * 2007-04-12 2014-09-23 Joyant Pharmaceuticals Inc Dímeros e trímeros miméticos de smac úteis como agentes anticâncer
WO2008128063A1 (en) * 2007-04-12 2008-10-23 Infinity Discovery, Inc. Hydroquinone ansamycin formulations
KR20100057007A (ko) * 2007-07-09 2010-05-28 글렌 에스. 권 치료제의 마이셀 캡슐화
US8551964B2 (en) 2007-08-23 2013-10-08 The Regents Of The University Of Colorado Hsp90 inhibitors with modified toxicity
JP2011501731A (ja) 2007-09-10 2011-01-13 ユニバーシティ オブ マサチューセッツ ミトコンドリア標的化抗腫瘍剤
CN103720701A (zh) * 2007-10-22 2014-04-16 逊尼希思制药公司 在联合治疗中使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸的方法
WO2009086170A1 (en) * 2007-12-21 2009-07-09 Joyant Pharmaceuticals, Inc. Diazonamide analogs with improved solubility
CN101220068B (zh) * 2008-01-18 2012-06-13 中国医学科学院医药生物技术研究所 一组格尔德霉素衍生物及其制备方法
US20090258869A1 (en) * 2008-02-08 2009-10-15 The Regents Of The University Of California Methods and compounds for treatment or prevention of substance-related disorders
US7989482B2 (en) * 2008-04-29 2011-08-02 Joyant Pharmaceuticals, Inc. Indoline anti-cancer agents
US8153619B2 (en) * 2008-05-22 2012-04-10 Joyant Pharmaceuticals, Inc. Diazonamide analogs
US8778921B2 (en) * 2008-10-15 2014-07-15 Infinity Pharmaceuticals, Inc. Ansamycin hydroquinone compositions
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
WO2011038278A2 (en) 2009-09-25 2011-03-31 Wisconsin Alumni Research Foundation Micelle encapsulation of therapeutic agents
JPWO2011040421A1 (ja) 2009-09-29 2013-02-28 武田薬品工業株式会社 スクリーニング方法
JP5529282B2 (ja) 2009-10-28 2014-06-25 ジョイアント ファーマスーティカルズ、インク． 二量体Ｓｍａｃ模倣薬
CN102603635B (zh) * 2011-01-21 2016-08-03 杭州华东医药集团生物工程研究所有限公司 格尔德霉素衍生物及其制备方法和用途
HRP20171930T1 (hr) 2011-04-22 2018-02-09 Joyant Pharmaceuticals, Inc. Analozi diazonamida
WO2012151544A1 (en) 2011-05-05 2012-11-08 Wisconsin Alumni Research Foundation Micelles for the solubilization of gossypol
CA2851383A1 (en) 2011-10-14 2013-04-18 Xizhong Huang 2 - carboxamide cycloamino urea derivatives in combination with hsp90 inhibitors for the treatment of proliferative diseases
US9603829B2 (en) 2011-11-14 2017-03-28 The Regents Of The University Of Colorado, A Body Corporate HSP90 inhibitors with modified toxicity
WO2013105022A2 (en) 2012-01-09 2013-07-18 Novartis Ag Organic compositions to treat beta-catenin-related diseases
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
WO2014055624A1 (en) 2012-10-02 2014-04-10 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods relating to dna-sensing pathway related conditions
AU2013341271A1 (en) 2012-11-07 2015-05-14 Novartis Ag Combination therapy
BR112015018882B1 (pt) 2013-02-19 2021-09-14 Novartis Ag Derivados de benzotiofeno e composições dos mesmos como degradadores de receptor de estrogênio seletivo
CN103360312B (zh) * 2013-07-22 2015-06-03 山东大学 一组格尔德霉素衍生物及其应用
CN105764502A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群及其类似物及衍生物的治疗益处的组合方法
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
JP6473457B2 (ja) 2014-01-17 2019-02-20 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための１−（トリアジン−３−イル／ピリダジン−３−イル）−ピペリジン／ピペラジン誘導体およびその組成物
ES2699351T3 (es) 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
KR20170129757A (ko) 2015-03-25 2017-11-27 노파르티스 아게 Fgfr4 억제제로서의 포르밀화 n-헤테로시클릭 유도체
EP3307264A1 (en) 2015-06-12 2018-04-18 Wisconsin Alumni Research Foundation Multi-drug combinations that act as potent radiosensitizers
WO2016203404A1 (en) 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
US10308660B2 (en) 2015-06-19 2019-06-04 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
JP6718889B2 (ja) 2015-06-19 2020-07-08 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための化合物および組成物
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
CN109415343A (zh) 2016-05-04 2019-03-01 基因科学医药公司 用于治疗增殖性疾病的取代的2,4-二氨基-喹啉衍生物
RU2021106500A (ru) 2016-06-14 2021-04-16 Новартис Аг Соединения и композиции для подавления активности shp2
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
US10435389B2 (en) 2017-09-11 2019-10-08 Krouzon Pharmaccuticals, Inc. Octahydrocyclopenta[c]pyrrole allosteric inhibitors of SHP2
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
PT3826686T (pt) 2018-07-25 2025-08-04 Advanced Accelerator Applications S A Soluções estáveis de complexo de radionuclídeo concentrado
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
CA3113234A1 (en) 2018-09-18 2020-03-26 Nikang Therapeutics, Inc. Tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors
WO2020068867A1 (en) 2018-09-25 2020-04-02 Black Diamond Therapeutics, Inc. Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
JP7358484B2 (ja) 2018-09-25 2023-10-10 アドヴァンスド・アクセラレーター・アプリケーションズ・（イタリー）・エッセエッレエッレ 併用療法
JP2022502496A (ja) 2018-09-25 2022-01-11 ブラック ダイアモンド セラピューティクス，インコーポレイティド チロシンキナーゼ阻害剤組成物、作製方法、および使用方法
WO2020065453A1 (en) 2018-09-29 2020-04-02 Novartis Ag Process of manufacture of a compound for inhibiting the activity of shp2
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP7483732B2 (ja) 2019-02-15 2024-05-15 ノバルティス アーゲー ３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
BR112022002518A2 (pt) 2019-08-15 2022-07-19 Black Diamond Therapeutics Inc Compostos de alquinila quinazolina
US20230056470A1 (en) 2019-12-20 2023-02-23 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
WO2021195206A1 (en) 2020-03-24 2021-09-30 Black Diamond Therapeutics, Inc. Polymorphic forms and related uses
BR112022026202A2 (pt) 2020-06-23 2023-01-17 Novartis Ag Regime de dosagem compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
CN116134027B (zh) 2020-08-03 2025-01-24 诺华股份有限公司 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
WO2022043556A1 (en) 2020-08-31 2022-03-03 Novartis Ag Stable radiopharmaceutical composition
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
EP4204020A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
US20250018049A1 (en) 2020-12-22 2025-01-16 Nikang Therapeutics, Inc. Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
JP2024504932A (ja) 2021-01-13 2024-02-02 モンテ ローザ セラピューティクス， インコーポレイテッド イソインドリノン化合物
WO2022170052A1 (en) 2021-02-05 2022-08-11 Black Diamond Therapeutics, Inc. Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022219407A1 (en) 2021-04-14 2022-10-20 Monte Rosa Therapeutics Ag Isoindolinone compounds
EP4323349A1 (en) 2021-04-14 2024-02-21 Monte Rosa Therapeutics AG Isoindolinone amide compounds useful to treat diseases associated with gspt1
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
CN117980310A (zh) 2021-07-14 2024-05-03 尼坎治疗公司 作为kras抑制剂的亚烷基衍生物
KR20240167846A (ko) 2022-03-28 2024-11-28 니캉 테라퓨틱스 인코포레이티드 사이클린 의존적 키나제 2 억제제로서의 설폰아미도 유도체
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2023240024A1 (en) 2022-06-08 2023-12-14 Nikang Therapeutics, Inc. Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
KR20250103630A (ko) 2022-11-11 2025-07-07 니캉 테라퓨틱스 인코포레이티드 유비퀴틴 프로테아좀 경로를 통해 사이클린-의존성 키나제 2를 분해하기 위한 2,5-치환된 피리미딘 유도체를 함유하는 이작용성 화합물
WO2025072462A1 (en) 2023-09-27 2025-04-03 Nikang Therapeutics, Inc. Sulfonamide derivatives as cyclin-dependent kinase 2 inhibitors
TW202527955A (zh) 2023-11-27 2025-07-16 美商尼坎醫療公司 用於經由泛素蛋白酶體途徑降解週期蛋白依賴性激酶２和週期蛋白依賴性激酶４的含有２，５－取代的嘧啶衍生物的雙功能化合物
WO2025117981A1 (en) 2023-12-02 2025-06-05 Nikang Therapeutics, Inc. Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987035A (en) * 1974-04-05 1976-10-19 University Of Illinois Foundation Biologically active compounds

Also Published As

Publication number Publication date
AU5443080A (en) 1980-08-28
IT8020017A0 (it) 1980-02-19
GB2042523A (en) 1980-09-24
IT1147315B (it) 1986-11-19
DE3006097C2 (en:Method) 1991-11-07
CA1113935A (en) 1981-12-08
FR2449084A1 (fr) 1980-09-12
NL8000857A (nl) 1980-08-21
GB2042523B (en) 1983-02-09
AU532333B2 (en) 1983-09-29
US4261989A (en) 1981-04-14
DE3006097A1 (de) 1980-08-28

Similar Documents

Publication Publication Date Title
FR2449084B1 (en:Method)
BR8002583A (en:Method)
BR8006808A (en:Method)
FR2449969B1 (en:Method)
FR2449128B1 (en:Method)
FR2446676B1 (en:Method)
FR2447021B1 (en:Method)
FR2449355B1 (en:Method)
FR2448229B1 (en:Method)
FR2448462B1 (en:Method)
FR2450616B1 (en:Method)
FR2446344B1 (en:Method)
AU79557S (en:Method)
AU78569S (en:Method)
AU79200S (en:Method)
AU78271S (en:Method)
AU78391S (en:Method)
BR5901094U (en:Method)
AU78270S (en:Method)
AU79558S (en:Method)
AU79559S (en:Method)
AU77763S (en:Method)
AU79918S (en:Method)
AU79950S (en:Method)
AU80228S (en:Method)

Legal Events

Date Code Title Description
ST Notification of lapse